Asset profile
CR-001
Multispecific antibody
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
13 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 13 same-indication; 1 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| CR-001: this drug | Phase 1/2 | Multispecific antibody | — | ||
| RP2 | Phase 2/3 | Oncolytic Virus | — | ||
| ALG.APV-527 | Phase 1/2 | Multispecific antibody | — | ||
| BT5528 | Phase 1/2 | Peptide | EphA2 | ||
| LP-184 | Phase 1/2 | Small molecule | PTGR1 (Prostaglandin Reductase 1, bioactivating enzyme) | ||
| PYX-201 | Phase 1/2 | Small molecule | — | ||
| Rezatapopt | Phase 1/2 | Small molecule | p53 reactivator | ||
| XTX501 | Phase 1/2 | Multispecific antibody | PD-1/PD-L1 axis; IL-2 receptor βγ (IL-2Rβγ) | ||
| BBO-10203 | Phase 1 | Small molecule | RAS:PI3Kα protein-protein interaction | ||
| COM902 | Phase 1 | Monoclonal antibody | TIGIT | ||
| JANX008 | Phase 1 | Small molecule | EGFR | ||
| NXP900 | Phase 1 | Small molecule | SRC and YES1 (Src-family kinases) | ||
| RP3 | Phase 1 | Oncolytic Virus | — | ||
| Linebacker | Not yet studied | Small molecule | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2029 (1)
February 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.